Summary The matrix metalloproteinase inhibitor batimastat was administered to a human colorectal cancer ascites model, which was initiated by injection of C170HM2 cells into the peritoneal cavity of SCID mice and resulted in solid tumour deposits and ascites formation. The cell line expressed both the 72 and 92 kDa forms of gelatinase by zymography. Batimastat administered from day 0 (40 mg kg-1) reduced the volume of ascites to 21 % of control in mice treated from day 0 (P <0.002) but not day 10. Formation of solid peritoneal deposits was significantly reduced to 77% of vehicle control when batimastat was administered from day 0 (P<0.01) and 69% of control when administered from day 10 (P<0.05). Thus, batimastat has the ability to reduce the volume of ascites forming in SCID mice injected intraperitoneally with the human colorectal cell line, C170HM2, when administered from day 0 but not from day 10. Solid peritoneal tumour deposits were significantly reduced in both treatment groups, highlighting the therapeutic potential of batimastat in this clinical condition.
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Keywords: metalloproteinase; colorectal cancer; batimastat A large body of evidence now suggests that matrix metalloproteinases (MMPs) play a role in the metastasis of tumour cells (Brown, 1993) . Secretion of these enzymes by both normal and malignant cells is in the form of a latent precursor, which is activated by removal of an amino terminal domain (Stetler-Stevenson et al., 1989) . These enzymes are implicated in the breakdown of extracellular matrix and vascularisation, which are both critical for successful metastasis, and recent clinical studies have shown MMP to play a role in the spread of human tumour cells Davies et al., 1993) .
The role of individual enzymes from the MMP family, in both the growth and metastatic spread of colorectal tumours, has been investigated. Activity of type I fibrillar collagenase, a member of the MMP family, has been shown to correlate with histological grade (van der Strappen, 1990) . The 72 kDa gelatinase, which breaks down type IV collagenase of basement membrane, correlates with tumour progression, and mRNA studies have revealed the presence of this enzyme in the tissue stroma adjacent to the invasive edge of the cancer (D'Errico et al., 1991; Poulson et al., 1992) . The 92 kDa form of gelatinase has been demonstrated by immunocytochemistry to be widespread in colorectal carcinoma, especially in tumours of advanced stage (Jeziorska et al., 1994) . In the same study, expression of the enzyme at specific sites in the tumour has been shown to be inversely related to the localisation of type IV collagen. Furthermore, the 92 kDa gelatinase is elevated in the plasma of colon cancer patients (Zucker et al., 1993) . In a study evaluating stromelysins 1 and 2 and matrilysin (PUMP-1) expression in colorectal cancer, the mRNA of the latter enzyme was expressed in 75% of colon carcinomas, whereas the mRNA of the former was not detected (McDonnell et al., 1991) . In a recent study, stromelysin 3 mRNA was overexpressed in primary colorectal adenocarcinomas and liver metastases and expression was shown in stromal fibroblasts adjacent to the neoplastic lesions (Porte et al., 1995) .
A study examining collective expression of gelatinases and matrilysin suggested that the latter may participate early in tumour progression, whereas the former enzymes, in conjunction with matrilysin and other members of the MMP family, may mediate events occurring later in the progressive cascade (Newell et al., 1994) .
The synthetic metalloproteinase inhibitor, batimastat, has broad spectrum and potent activity against many members of the MMP family (Brown, 1993) and has been shown to inhibit the metastatic spread of the B16 murine melanoma (Chirivi et al., 1994) and the lung and liver colonisation of the human colorectal tumours, AP5LV and C1 70HM2 respectively (Watson et al., 1995) . In addition, the agent has been shown to inhibit tumour growth in an ovarian ascites model (Davies et al., 1993) . Owing to the pharmacokinetics of the drug, it has potential therapeutic use in cases of malignant ascites and has been evaluated in clinical patients with ascites of malignant origin (SL Parsons et al. unpublished data) . This study sets out to determine the direct effects of batimastat on tumour growth in an aggressive ascites model initiated by a gastrointestinal cancer cell line.
Materials and methods
Cell line C170HM2 ascites is a human colorectal tumour cell line selected to yield an end point of ascites after administration of the parental line, C17OHM2 (Watson et al., 1993) In vivo therapy Table I shows the incidence of C17OHM2-induced ascites in mice treated from day 0 with batimastat and those with treatment delayed until day 10. Batimastat treatment from day 0 reduced the incidence of ascites from 100% in the matching vehicle control to 53% in the treated group, which just failed to reach statistical significance (P = 0.07, chi-squared test). When treatment was delayed until day 10, the incidence was reduced from 93% to 67%, which was not significantly different. The volume of accumulated ascites is shown in Figure 2a Figure   2b includes only mice developing ascites. With all experimental animals included, mice treated with batimastat from day 0 had significantly reduced volumes of ascites (21 % of control) when compared with the vehicle control, which was statistically significant (P < 0.001, Student's t-test). However, a significantly different ascites volume was not achieved when batimastat was administered from day 10 (Figure 2a) . When including only experimental mice that accumulated ascites, those treated with batimastat from day 0 had a significantly reduced volume when compared with the vehicle controls (P < 0.002, Student's t-test), but not when administered from day 10 (Figure 2b) . Table II further summarises the ascites formation in the four groups of experimental animals (with only animals accumulating ascites included). Days to ascites was not significantly altered in both treatment groups when compared with the corresponding controls.
Viability of the cells in the ascites fluid in all groups was high (>90%), with no statistically significant difference seen between the four groups (Table II) . The cell density of the accumulated ascites was also not significantly different between the four treatment groups, ranging from 1.6 x 106 to 3.2 x 106 cells ml -1 (Table II) .
Peritoneal tumour weights are shown in Figure 3 . There was a significant reduction in peritoneal tumour weight in both batimastat-treated groups; 77% of control for treatment from day 0, P<0.01 and 69% of control following treatment from day 10, P<0.05. (Watson et al., 1995) . Thus, although the mechanisms of action of batimastat have not been confirmed, the studies performed so far indicate that the drug may inhibit tumour growth, possibly by preventing new invasive growth and by inhibiting neovascularisation.
The present study has evaluated the effect of batimastat on a human colorectal ascites model. A similar study, performed in a human ovarian ascites model in nude mice (Davies et al., 1993) , showed batimastat to induce a resolution of ascites and an enhancement of survival. Histological observations revealed that, following treatment, free-floating ascitic cells had reverted to solid tumours surrounded by a capsule of host tissue. Batimastat was postulated to induce its antitumour effect by promoting the synthesis of stromal connective tissue by blocking the equilibrium between synthesis and degradative pathways.
Clinically, batimastat has been used to treat malignant ascites from a gastrointestinal (GI) origin. In a recent study by SL Parsons et al. (unpublished data) , batimastat showed encouraging results in malignant ascites. As GI malignant ascites is a more aggressive condition than that of ovarian ascites, it was decided to investigate the inhibitory effects of batimastat on tumour growth in an aggressive in vivo GI ascites model.
In the present study, batimastat inhibited ascites formation in 47% of the animals and reduced the accumulation in the remaining animals, when given from the time of tumour cell injection. Solid peritoneal tumour growth was also reduced. The results from the group given batimastat 10 days after cell injections indicates that batimastat is unable to inhibit ascites formation but can affect the growth of solid tumour deposits. In the GI ascites model free-floating ascitic cells were still present following batimastat treatment, unlike the ovarian ascites model described by Davies et al. (1993) . This could reflect differences in tumour growth rate in the two models. I-n the present study, inhibition of solid tumour growth was equivalent when batimastat was given from day 0 and day 10. This indicates that batimastat inhibition occurred at > 10 days of tumour growth, possibly during the phase when neovascularisation may have been maximal. In a previous model it has been shown that batimastat has the potential to inhibit angiogenesis (Taraboletti et al., 1995) .
It is known that these effects could not be attributed to non-specific cytotoxic effects on the cells, as a wide range of batimastat concentrations (0.01-5 ,ug ml-') has previously been shown not to affect the in vitro proliferation of Cl7OHM2 cells (Watson et al., 1995) . In addition, in the liver invasive model involving C170HM2 in nude mice (Watson et al., 1995) , an inactive isomer of batimastat, BB1268, had no inhibitory effects on tumour growth. In fact the agent stimulated tumour growth, which was postulated to be caused by non-specific blockade of the reticuloendothelial system, resulting in enhanced accumulation of tumour cells within the peritoneal cavity. Thus, any therapeutic effects seen both in the liver-invasive model and in the present ascites model is unlikely to be attributable to administration of the drug and tumour cells both directly into the peritoneal cavity.
The role of MMPs in ascites formation is unclear but, in accordance with Davies et al. (1993) , the present study does provide additional evidence that metalloproteinases are involved in maintaining the stromal equilibrium necessary to ensure that ascitic cells remain in a suspension form. In addition, as volume was suppressed greatly by batimastat in the present study, it may be that metalloproteinases have a role to play in vascular permeability mediating fluid accumulation in the peritoneal cavity, which may provide a source of nutrients for the tumour cells present. One agent involved in this process is vascular permeability factor, which is abundant in tumour ascites fluid (Senger et al., 1983) and is secreted by a number of human tumour types (Senger et al., 1986) , including colorectal (Lobb et al., 1985) . It is, therefore, possible that MMP inhibitors may either directly or indirectly inhibit secretion of tumour-associated permeability factors, which would explain their potent therapeutic effect in both the ovarian and the present colorectal ascites model.
Thus, batimastat appears to be therapeutically active in a colorectal cancer ascites model by preventing ascites formation and reducing the solid tumour burden within the peritoneal cavity. These findings have important implications for the therapeutic potential of batimastat in this area.
